

ASX Release

24th November 2015

PharmAust Appoints RedChip to undertake Global Investor Relations Program

PharmAust Limited (“PharmAust”) (ASX: PAA) is pleased to report that it has appointed RedChip Companies (“RedChip”) to provide a comprehensive global investor relations program to expand the Company’s retail and institutional shareholder base in the U.S, Europe, Asia and Latin America.

RedChip is a world leader in investor relations, financial media, and research for microcap, small-cap, and mid-cap stocks. Founded in 1992 and headquartered in Orlando, Florida, with affiliates in New York, Pittsburgh, Paris and Seoul, RedChip has helped hundreds of companies achieve their capital markets goals and has been ranked by Inc. Magazine as one of the fastest growing privately held investor relations firms in the U.S. RedChip’s platform includes a weekly television show, “The RedChip Money Report,” which reaches more than 160 million households in Australia, Europe, Asia, and Latin America (<http://www.redchip.com/tv>).

Following successful completion of its Phase I/II trial at the Royal Adelaide Hospital, with its targeted cancer therapy product (PPL-1/monepantel) and similar safety/efficacy trial in canines, PharmAust will now move forward with its planned Phase II trial and will also progress discussions around its Research and Option Agreement with Novartis Animal Health and expand both its clinical activities and investor base in the US and Europe. Key activities for Q1 2016 will be the completion of the reformulation and manufacture of a tasteless format of monepantel as well as initiation Phase II.

RedChip has now commenced execution of an investor relations program to showcase PharmAust’s product pipeline to retail and institutional investors globally.

As part of this process, RedChip will prepare and release a research report on PharmAust.

RedChip’s CEO and President David Gentry said: “We are delighted to showcase PharmAust in the U.S. and across the world with our multimedia and digital platform. The fact that PharmAust is now preparing for a Phase II clinical trial with its lead drug monepantel puts them at a major inflection point. PharmAust’s lead oncology program uniquely positions the Company in the fastest growing pharmaceutical market in the world”.

About RedChip Companies:

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. For 23 years, RedChip has delivered concrete, measurable results for its clients. Our digital magazine, the RedChip Money Report is delivered on-line weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include the following: a worldwide distribution network for its stock research

For personal use only



written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 3.2 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually, a globally-televised show, "The RedChip Money Report," which airs weekly in 160 million homes in Europe, Asia, Latin America, and Australia on the Bloomberg network; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. Visit www.redchip.com for more information.

For further details please contact:

Dr. Roger Aston
Executive Chairman
Tel: 0402 762 204
rogeraston@pharmaust.com

Dave Gentry
President, RedChip Companies
Tel: 1-407-644-4256, ext. 104
dave@redchip.com

For personal use only